
Niagen Bioscience, Inc.: updates and filings
Price
$1.81
November 20, 2026Market cap $145M
What Ploutos Investor adds for Niagen Bioscience
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 26% since Nov 4, 2026, when the 10-Q these figures come from was filed ($2.52 then, $1.87 on Nov 19, 2026). The figures date from before that move.10-Q
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 9, 2026FilingFormEFFECT
- Jun 29, 2026Shareholder voteForm8-K
- Jun 29, 2026Shelf registration for future offeringsFormS-3
- May 6, 2026Results of operations, Regulation FD disclosureForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Mar 19, 2026Other material eventsForm8-K
- Mar 4, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 4, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Regulation FD disclosure, other material eventsForm8-K
- Jan 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Dec 22, 2025Material agreement entered, Regulation FD disclosureForm8-K
- Nov 6, 2025Other material eventsForm8-K
- Nov 4, 2025Results of operations, Regulation FD disclosureForm8-K
- Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Oct 31, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 6, 2025Regulation FD disclosureForm8-K
- Aug 8, 2025Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 9, 2026 | EFFECT | Filing | Document |
| Jun 29, 2026 | 8-K | Shareholder vote | Document |
| Jun 29, 2026 | S-3 | Shelf registration for future offerings | Document |
| May 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 19, 2026 | 8-K | Other material events | Document |
| Mar 4, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 4, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jan 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Dec 22, 2025 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Nov 6, 2025 | 8-K | Other material events | Document |
| Nov 4, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Oct 31, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 6, 2025 | 8-K | Regulation FD disclosure | Document |
| Aug 8, 2025 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 18, 2007.
The full analysis
What do Niagen Bioscience's filings show?
The filings are where every one of Niagen Bioscience's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.